News Sentiment

TIL sentiment intelligence

Instil Bio Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 42 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.70 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 34

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.4% over one week, -2.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Avoiding Lag: Real-Time Signals in (TIL) Movement

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend inactive -2.8% over four weeks
Fair value -51.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 26
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 34
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 7
TradingKey 7
Stock Titan 7
Stock Traders Daily 3
simplywall.st 2
The National Law Review 1
Simply Wall Street 1

Event Lens

What the news is about

Classified themes
Market update 18
Earnings 16
Deals and strategy 3
Balance sheet 2
Regulatory and legal 1
Capital return 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-42 of 42
Market source Direct company coverage

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio announced its first quarter 2026 financial results, highlighting a cash position of approximately $74.7 million as of March 31, 2026, which is expected to fund operations beyond 2027. The company is actively evaluating potential acquisitions and in-licensing opportunit

Tone
Positive 63/100
Event
Deals and strategy
Published
15 May 2026 11:09
Source
Market source
Stock Titan Direct company coverage

Instil Bio (NASDAQ: TIL) cuts Q1 loss as 2024 loan and going concern risk loom

Instil Bio (NASDAQ: TIL) significantly reduced its net loss to $4.2 million in Q1 2026 from $28.2 million a year prior, primarily due to lower operating expenses from restructuring and discontinuing its AXN-2510 program. Despite this, the company faces a going concern risk as its

Tone
Negative 40/100
Event
Balance sheet
Published
15 May 2026 10:40
Source
Stock Titan